NEWARK, Del, Jan. 11, 2023 (GLOBE NEWSWIRE) -- A recently published study by FMI expects the global PCSK9 inhibitors market to augment at a 15.8% CAGR from 2022 to 2032. By the end of the said ...

Eli Lilly is laying the groundwork for a phase 2 trial of the lipid-lowering gene editor it acquired from Verve Therapeutics, with the candidate now showing strong and consistent cholesterol ...

An experimental one-time gene editing therapy significantly lowered LDL cholesterol in an early-stage trial, raising hopes ...

Sweden: Laroprovstat, the first oral small-molecule PCSK9 inhibitor under clinical development, demonstrated substantial LDL cholesterol–lowering effects in a phase 1 study involving treatment-naive ...

Please provide your email address to receive an email when new articles are posted on . PCSK9 inhibitor prescriptions are rejected by insurers at a higher rate vs. other guideline-indicated ...

Please provide your email address to receive an email when new articles are posted on . Less frequent anti-PCSK9 monoclonal antibody dosing is possible with recaticimab. When dosed every 12 weeks, the ...

ATLANTA -- A novel PCSK9 inhibitor safely reduced LDL cholesterol levels with just a single, quick, once-monthly dose, the phase III LIBerate-HR trial showed. Lerodalcibep reduced LDL cholesterol by ...

Low back pain is a leading global cause of disability, and the musculoskeletal impact of lipid-lowering drugs (e.g., statins, PCSK9 inhibitors) used for coronary heart disease (CHD) prevention has ...

A single infusion of an experimental gene-editing drug seemed to reduce LDL long-term in a small trial. The results may point to something “curative,” one expert said.

WASHINGTON, DC — In order to be cost-effective for patients, providers, and payers, the new proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors would need to cost around $2400 per year, a mark ...